Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emerging applications of nanobodies in cancer therapy.
Awad RM, Meeus F, Ceuppens H, Ertveldt T, Hanssens H, Lecocq Q, Mateusiak L, Zeven K, Valenta H, De Groof TWM, De Vlaeminck Y, Krasniqi A, De Veirman K, Goyvaerts C, D'Huyvetter M, Hernot S, Devoogdt N, Breckpot K. Awad RM, et al. Among authors: goyvaerts c. Int Rev Cell Mol Biol. 2022;369:143-199. doi: 10.1016/bs.ircmb.2022.03.010. Epub 2022 May 18. Int Rev Cell Mol Biol. 2022. PMID: 35777863
Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy.
Van Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, Pen J, Bonehill A, Heirman C, Breckpot K, Thielemans K. Van Lint S, et al. Among authors: goyvaerts c. Cancer Res. 2012 Apr 1;72(7):1661-71. doi: 10.1158/0008-5472.CAN-11-2957. Epub 2012 Feb 15. Cancer Res. 2012. PMID: 22337996
Lentiviral vectors: a versatile tool to fight cancer.
Emeagi PU, Goyvaerts C, Maenhout S, Pen J, Thielemans K, Breckpot K. Emeagi PU, et al. Among authors: goyvaerts c. Curr Mol Med. 2013 May;13(4):602-25. doi: 10.2174/1566524011313040011. Curr Mol Med. 2013. PMID: 22973872 Review.
Targeting of human antigen-presenting cell subsets.
Goyvaerts C, Dingemans J, De Groeve K, Heirman C, Van Gulck E, Vanham G, De Baetselier P, Thielemans K, Raes G, Breckpot K. Goyvaerts C, et al. J Virol. 2013 Oct;87(20):11304-8. doi: 10.1128/JVI.01498-13. Epub 2013 Jul 17. J Virol. 2013. PMID: 23864630 Free PMC article.
Immunogenicity of targeted lentivectors.
Goyvaerts C, Kurt de G, Van Lint S, Heirman C, Van Ginderachter JA, De Baetselier P, Raes G, Thielemans K, Breckpot K. Goyvaerts C, et al. Oncotarget. 2014 Feb 15;5(3):704-15. doi: 10.18632/oncotarget.1680. Oncotarget. 2014. PMID: 24519916 Free PMC article.
Targeting the tumor microenvironment to enhance antitumor immune responses.
Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, Van Lint S, Heirman C, Thielemans K, Breckpot K. Van der Jeught K, et al. Among authors: goyvaerts c. Oncotarget. 2015 Jan 30;6(3):1359-81. doi: 10.18632/oncotarget.3204. Oncotarget. 2015. PMID: 25682197 Free PMC article. Review.
Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.
Liechtenstein T, Perez-Janices N, Blanco-Luquin I, Goyvaerts C, Schwarze J, Dufait I, Lanna A, Ridder M, Guerrero-Setas D, Breckpot K, Escors D. Liechtenstein T, et al. Among authors: goyvaerts c. Oncoimmunology. 2014 Jul 3;3(7):e945378. doi: 10.4161/21624011.2014.945378. eCollection 2014. Oncoimmunology. 2014. PMID: 25954597 Free PMC article.
46 results